A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
about
Infliximab-Related Infusion Reactions: Systematic ReviewInflammatory bowel diseases and human reproduction: a comprehensive evidence-based reviewInvasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitorsReview article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational studyDysregulation of anti-inflammatory annexin A1 expression in progressive Crohns DiseaseAnti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.Biologics in paediatric Crohn's disease.Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysisWhat is the impact of age on adult patients with inflammatory bowel disease?Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report.Severe cholestasis due to adalimumab in a Crohn's disease patient.TNF-α signaling in Fanconi anemia.Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Upregulated LINE-1 Activity in the Fanconi Anemia Cancer Susceptibility Syndrome Leads to Spontaneous Pro-inflammatory Cytokine Production.Hepatic manifestations of inflammatory bowel diseases.Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab.EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial.Intestinal superinfections in patients with inflammatory bowel diseases.A survey of applications of biological products for drug interference of immunogenicity assays.Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.Organising infusions: Application administration and complications.Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients.Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.
P2860
Q27013835-DA7FE7AC-6E62-4FC6-AC5F-AC61E677F3F8Q28388274-DFF64CAF-F5E1-40BF-9B8D-22F88AA87F52Q29302324-6B2E7045-F119-43AC-B8D2-D25CAF93766DQ33401933-0897AA46-7904-4229-ACFF-DCF18E9D5B3EQ33654733-BB381F64-32DC-4DDD-ABF7-0414544A1F30Q33805921-87E90DF9-A577-45A9-A5F8-9C900773AB47Q35018662-407074C7-8E78-460C-A9D5-7D0BFE487C60Q35526652-950E0FBD-B7E2-4830-89E7-C13166774A8EQ35579308-2D4B18C5-C7F9-411B-82DA-031FE58E5A00Q35679414-F48420D3-8363-463C-A8DD-C1EC34D49E29Q35714154-4E9B7C33-51CC-49C9-AACA-46F734E5B9ABQ36232337-64B9BCB8-8D6F-4E21-9D2E-E0D61FDAAD7DQ37266339-EF95607C-1743-4BCD-B1FB-038E4F120160Q38124483-E8FC4B10-0685-4A62-986B-6D7B8173EC58Q38210793-DE6AAAE1-E8E7-4706-9B05-C46CA3A794CBQ38652276-35445E1B-5B75-42A0-8D1A-5357F67D46E7Q38757484-22860525-9527-4986-8046-18CCBF323E22Q38814158-BFBFC019-E212-4426-A172-5CD603408D92Q38833346-F5A4562A-5D56-4184-B10F-A45129A25E57Q39435409-05B1B080-48FE-41FD-A33B-596EDD34D6CDQ39982504-CEC3E4AE-0471-41AB-9BFE-EE77AD3DB579Q41963904-4DDD363A-062B-40A3-BED3-07348B4AFBECQ42375893-20F06F7E-FED8-4A99-8334-03505EFBDA45Q44774030-916E0E3D-1EB4-4109-AE34-DF4A3A2F76B4Q47247174-BB0375E0-74A2-4DFA-A729-BAE119F4F595Q51036254-CC9CE633-41B7-4E3E-BF37-1B13441FF4D8Q51715014-BB929B1B-50AF-480E-BE98-B048CA9BE240Q53277640-47DDFDAE-D7AE-4FC2-B5A8-00A276F498C1Q55114620-BFD6B015-B795-4DA6-BE64-51128ED25071
P2860
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A decade of infliximab: The Au ...... in inflammatory bowel disease.
@en
A decade of infliximab: The Au ...... in inflammatory bowel disease.
@nl
type
label
A decade of infliximab: The Au ...... in inflammatory bowel disease.
@en
A decade of infliximab: The Au ...... in inflammatory bowel disease.
@nl
prefLabel
A decade of infliximab: The Au ...... in inflammatory bowel disease.
@en
A decade of infliximab: The Au ...... in inflammatory bowel disease.
@nl
P2093
P2860
P1476
A decade of infliximab: The Au ...... in inflammatory bowel disease
@en
P2093
Austrian Society of Gastroenterology and Hepatology
H Vogelsang
P Knoflach
P2860
P304
P356
10.1016/J.CROHNS.2009.12.001
P577
2010-03-17T00:00:00Z